Company intelligence / Profile preview
Kuda Therapeutics
Boston, Massachusetts, United Stateskudatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Kuda Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics that target the mitochondrial pyruvate carrier (MPC). By modulating the transport of pyruvate into the mitochondria, the company aims to address fundamental metabolic imbalances that drive chronic diseases. Their primary research efforts are directed toward metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and certain oncology indications. Kuda's approach leverages deep expertise in mitochondrial biology to create first-in-class treatments for patients with high unmet medical needs.
- Therapeutic areas
- Metabolic DisordersGastroenterologyEndocrinologyNephrologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kuda Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kuda Therapeutics.